fashion -WSS

fashion

author：Wikipedia 2025-10-01 00:00:13 - browse：545

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： This gene therapy has record $4.25 million price. It's saved children.

entertainment

WSS

Mirador, a new biotech startup, launches with $400 million

Mirador, a new biotech startup, launches with $400 million

Pfizer, Moderna say biotech, pharma drug development is a sprint

ALS patient reclaims some autonomy thanks to wearable 'robot'

Cigna wins case to block Amy Bricker's move to CVS

Biotech investment managers search for lucrative opportunities

leisure time

fashion

leisure time

Activists slam private health insurers over coverage restrictions

My daughter's legacy lives on through her writing, phage therapy

Psychedelics group wrestles with new pharma identity

U.K. officials, researchers try to ease path for bespoke genetic treatments

Drug repurposing or repositioning? The language matters

Cheap, fast test for Zika and dengue could cost just $1

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Trump demands the U.S. pay no more for drugs than other countries … again

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

U.K. officials, researchers try to ease path for bespoke genetic treatments

California wildfire smoke linked to 52,000 early deaths, study says

Deposition: Sackler embraced plan to conceal OxyContin’s strength

How faith leaders like me can help address America's obesity epidemic

ALS patient reclaims some autonomy thanks to wearable 'robot'

Diabetes management: Digital health tools fall short, study says

Wikipedia

leisure time

entertainment

Wikipedia